{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:24:02Z","timestamp":1770315842145,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The National Key Research and Development Program of China","award":["2021YFC2500300"],"award-info":[{"award-number":["2021YFC2500300"]}]},{"name":"2023 Peking University People's Hospital Research and Development Fund Clinical Research Cultivation Project","award":["RDL2023-08"],"award-info":[{"award-number":["RDL2023-08"]}]},{"name":"CAMS Innovation Fund for Medical Science","award":["2023-12M-C&T-B-123"],"award-info":[{"award-number":["2023-12M-C&T-B-123"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06802-x","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:57:28Z","timestamp":1768442248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating FLT3-ITD molecular features with clinical risk factors improves risk stratification in acute myeloid leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Kainan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guorui","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"6802_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"key":"6802_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","volume":"96","author":"G Nagel","year":"2017","unstructured":"Nagel G, Weber D, Fromm E et al (2017) Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol 96:1993\u20132003. https:\/\/doi.org\/10.1007\/s00277-017-3150-3","journal-title":"Ann Hematol"},{"key":"6802_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/bjh.16356","volume":"188","author":"S Charrot","year":"2020","unstructured":"Charrot S, Armes H, Rio-Machin A, Fitzgibbon J (2020) AML through the prism of molecular genetics. Br J Haematol 188:49\u201362. https:\/\/doi.org\/10.1111\/bjh.16356","journal-title":"Br J Haematol"},{"key":"6802_CR4","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","volume":"6","author":"T Grafone","year":"2012","unstructured":"Grafone T, Palmisano M, Nicci C, Storti S (2012) An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev 6:e8. https:\/\/doi.org\/10.4081\/oncol.2012.e8","journal-title":"Oncol Rev"},{"key":"6802_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.stem.2011.04.021","volume":"9","author":"SW Boyer","year":"2011","unstructured":"Boyer SW, Schroeder AV, Smith-Berdan S, Forsberg EC (2011) All hematopoietic cells develop from hematopoietic stem cells through Flk2\/Flt3-positive progenitor cells. Cell Stem Cell 9:64\u201373. https:\/\/doi.org\/10.1016\/j.stem.2011.04.021","journal-title":"Cell Stem Cell"},{"key":"6802_CR6","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","volume":"99","author":"JU Kazi","year":"2019","unstructured":"Kazi JU, R\u00f6nnstrand L (2019) FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications. Physiol Rev 99:1433\u20131466. https:\/\/doi.org\/10.1152\/physrev.00029.2018","journal-title":"Physiol Rev"},{"key":"6802_CR7","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374:2209\u20132221. https:\/\/doi.org\/10.1056\/NEJMoa1516192","journal-title":"N Engl J Med"},{"key":"6802_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33:299. https:\/\/doi.org\/10.1038\/s41375-018-0357-9","journal-title":"Leukemia"},{"key":"6802_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-00050-x","author":"T Casta\u00f1o-Bonilla","year":"2021","unstructured":"Casta\u00f1o-Bonilla T, Alonso-Dominguez JM, Barrag\u00e1n E et al (2021) Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-021-00050-x","journal-title":"Sci Rep"},{"key":"6802_CR10","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1038\/bcj.2015.61","volume":"5","author":"Y Kim","year":"2015","unstructured":"Kim Y, Lee GD, Park J et al (2015) Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length. Blood Cancer J 5:e336. https:\/\/doi.org\/10.1038\/bcj.2015.61","journal-title":"Blood Cancer J"},{"key":"6802_CR11","first-page":"318","volume":"30","author":"S Khaled","year":"2016","unstructured":"Khaled S, Al Malki M, Marcucci G (2016) Acute myeloid leukemia: biologic, prognostic, and therapeutic insights. Oncol (Williston Park) 30:318\u2013329","journal-title":"Oncol (Williston Park)"},{"key":"6802_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.hoc.2011.09.018","volume":"25","author":"D Grimwade","year":"2011","unstructured":"Grimwade D, Mr\u00f3zek K (2011) Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am 25:1135\u20131161. https:\/\/doi.org\/10.1016\/j.hoc.2011.09.018","journal-title":"Hematol Oncol Clin North Am"},{"key":"6802_CR13","doi-asserted-by":"publisher","unstructured":"(2018) The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia. Blood 131:1148\u20131153. https:\/\/doi.org\/10.1182\/blood-2017-09-807438","DOI":"10.1182\/blood-2017-09-807438"},{"key":"6802_CR14","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","volume":"107","author":"DL Stirewalt","year":"2006","unstructured":"Stirewalt DL, Kopecky KJ, Meshinchi S et al (2006) Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 107:3724\u20133726. https:\/\/doi.org\/10.1182\/blood-2005-08-3453","journal-title":"Blood"},{"key":"6802_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","volume":"36","author":"FG R\u00fccker","year":"2022","unstructured":"R\u00fccker FG, Du L, Luck TJ et al (2022) Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia 36:90\u201399. https:\/\/doi.org\/10.1038\/s41375-021-01323-0","journal-title":"Leukemia"},{"key":"6802_CR16","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.3390\/cancers15112991","volume":"15","author":"TR Haage","year":"2023","unstructured":"Haage TR, Schraven B, Mougiakakos D, Fischer T (2023) How ITD insertion sites orchestrate the biology and disease of FLT3-ITD-mutated acute myeloid leukemia. Cancers (Basel) 15:2991. https:\/\/doi.org\/10.3390\/cancers15112991","journal-title":"Cancers (Basel)"},{"key":"6802_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41408-020-0318-1","volume":"10","author":"I Abou Dalle","year":"2020","unstructured":"Abou Dalle I, Ghorab A, Patel K et al (2020) Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10:48. https:\/\/doi.org\/10.1038\/s41408-020-0318-1","journal-title":"Blood Cancer J"},{"key":"6802_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6802_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/bioinformatics\/btu593","volume":"31","author":"K Chiba","year":"2015","unstructured":"Chiba K, Shiraishi Y, Nagata Y et al (2015) Genomon ITDetector: a tool for somatic internal tandem duplication detection from cancer genome sequencing data. Bioinformatics 31:116\u2013118. https:\/\/doi.org\/10.1093\/bioinformatics\/btu593","journal-title":"Bioinformatics"},{"key":"6802_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.16526","volume":"190","author":"Y-L Zhou","year":"2020","unstructured":"Zhou Y-L, Wu L-X, Peter Gale R et al (2020) Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). Br J Haematol 190:274\u2013283. https:\/\/doi.org\/10.1111\/bjh.16526","journal-title":"Br J Haematol"},{"key":"6802_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R et al (2023) Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21:503\u2013513. https:\/\/doi.org\/10.6004\/jnccn.2023.0025","journal-title":"J Natl Compr Canc Netw"},{"key":"6802_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"6802_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1046\/j.1365-2141.2000.02317.x","volume":"111","author":"FM Abu-Duhier","year":"2000","unstructured":"Abu-Duhier FM, Goodeve AC, Wilson GA et al (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 111:190\u2013195. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02317.x","journal-title":"Br J Haematol"},{"key":"6802_CR24","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","volume":"99","author":"C Thiede","year":"2002","unstructured":"Thiede C, Steudel C, Mohr B et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis: Presented in part at the 42nd Annual Meeting of the American Society of Hematology, December 1\u20135, 2000, San Francisco, CA (abstract 2334). Blood 99:4326\u20134335. https:\/\/doi.org\/10.1182\/blood.V99.12.4326","journal-title":"Blood"},{"key":"6802_CR25","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.2174\/0109298673277543231205072556","volume":"31","author":"C Ma","year":"2024","unstructured":"Ma C, Cui S, Xu R (2024) Developments of Fms-like tyrosine kinase 3 inhibitors as anticancer agents for AML treatment. Curr Med Chem 31:4657\u20134686. https:\/\/doi.org\/10.2174\/0109298673277543231205072556","journal-title":"Curr Med Chem"},{"key":"6802_CR26","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00277-023-05545-3","volume":"103","author":"CJ Lap","year":"2024","unstructured":"Lap CJ, Abrahim MS, Nassereddine S (2024) Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia. Ann Hematol 103:2215\u20132229. https:\/\/doi.org\/10.1007\/s00277-023-05545-3","journal-title":"Ann Hematol"},{"key":"6802_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-023-00839-1","volume":"13","author":"G O\u00f1ate","year":"2023","unstructured":"O\u00f1ate G, Pratcorona M, Garrido A et al (2023) Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer J 13:69. https:\/\/doi.org\/10.1038\/s41408-023-00839-1","journal-title":"Blood Cancer J"},{"key":"6802_CR28","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cancers15041312","volume":"15","author":"M Jentzsch","year":"2023","unstructured":"Jentzsch M, Bischof L, Brauer D et al (2023) Clinical implications of the FLT3-ITD allelic ratio in acute myeloid leukemia in the context of an allogeneic stem cell transplantation. Cancers (Basel) 15:1312. https:\/\/doi.org\/10.3390\/cancers15041312","journal-title":"Cancers (Basel)"},{"key":"6802_CR29","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M, Brunet S, Nomded\u00e9u J et al (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 121:2734\u20132738. https:\/\/doi.org\/10.1182\/blood-2012-06-431122","journal-title":"Blood"},{"key":"6802_CR30","doi-asserted-by":"publisher","unstructured":"Schlenk RF, Kayser S, Bullinger L et al (2014) Differential impact of allelic ratio and insertion site in FLT3-ITD\u2013positive AML with respect to allogeneic transplantation. Blood 124:3441\u20133449. https:\/\/doi.org\/10.1182\/blood-2014-05-578070","DOI":"10.1182\/blood-2014-05-578070"},{"key":"6802_CR31","doi-asserted-by":"publisher","first-page":"8457","DOI":"10.1002\/cam4.3467","volume":"9","author":"R-Q Wang","year":"2020","unstructured":"Wang R-Q, Chen C-J, Jing Y et al (2020) Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med 9:8457\u20138467. https:\/\/doi.org\/10.1002\/cam4.3467","journal-title":"Cancer Med"},{"key":"6802_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/blood.2018862383","volume":"134","author":"S Garg","year":"2019","unstructured":"Garg S, Reyes-Palomares A, He L et al (2019) Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. Blood 134:263\u2013276. https:\/\/doi.org\/10.1182\/blood.2018862383","journal-title":"Blood"},{"key":"6802_CR33","doi-asserted-by":"publisher","first-page":"10410","DOI":"10.3390\/curroncol30120759","volume":"30","author":"J Bergeron","year":"2023","unstructured":"Bergeron J, Capo-Chichi J-M, Tsui H et al (2023) The clinical utility of FLT3 mutation testing in acute leukemia: a Canadian consensus. Curr Oncol 30:10410\u201310436. https:\/\/doi.org\/10.3390\/curroncol30120759","journal-title":"Curr Oncol"},{"key":"6802_CR34","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1111\/cas.13835","volume":"109","author":"S Liu","year":"2018","unstructured":"Liu S, Qiu Q, Bao X et al (2018) Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia. Cancer Sci 109:3981\u20133992. https:\/\/doi.org\/10.1111\/cas.13835","journal-title":"Cancer Sci"},{"key":"6802_CR35","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776\u20132784. https:\/\/doi.org\/10.1182\/blood-2007-08-109090","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06802-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:33:30Z","timestamp":1770262410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6802"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06802-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki; the protocol and experiment proposal related to the study were reviewed and approved by the Medical Ethics Committee of Peking University People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided informed consent before treatment, allowing their clinical data to be used for research purposes and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate declaration and publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}